1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
ConvaTec Group Plc

ConvaTec Group Plc

CNVVY
ConvaTec Group PlcUS flagOther OTC
11.02
USD
+0.18
- -
5.38BMarket Cap
ConvaTec Group Plc
CNVVY
(Other OTC)

Recent

price

11.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
3.49
3.55
3.38
4.91
3.62
3.75
3.71
3.8
4.06
4.1
4.2
4.47
4.82
Revenue per Share
0.03
-0.26
-0.19
-0.59
0.32
0.45
0.02
0.23
0.23
0.12
0.26
0.37
0.35
Basic EPS, GAAP
0.39
0.21
0.13
0.02
0.45
0.57
0.69
0.63
0.42
0.27
0.47
0.54
0.56
Free Cash Flow per Basic Share
1.78
- -
- -
- -
0.05
0.15
0.16
0.13
0.17
0.17
0.22
0.25
0.28
Dividend per Share
0.07
-0.2
-4.69
-7.01
-1.25
-1.03
-1.23
-1.2
-1.18
-1.27
-1.25
-1.13
-1.07
Book Value per Share
-6.65
-6.37
-6.08
-3.47
-2.12
-1.55
-1.23
-0.84
-0.72
-1.07
-1.06
-0.8
-0.94
Tangible Book Value per Share
488
488
488
344
488
489
493
498
502
506
510
512
506
Basic Weighted Avg Shares
1,701
1,734
1,650
1,688
1,765
1,832
1,827
1,894
2,038
2,072
2,142
2,289
2,439
Sales/Revenue/Turnover
18.09
12.62
13.96
9.12
14.04
14.61
5.3
11.14
9.99
10.67
12.38
14.5
15.83
Operating Margin (%)
189
192
181
182
179
190
210
198
211
209
215
221
224
Depreciation Expense
15
-127
-93
-203
158
222
10
112
118
63
130
191
175
Net Income, GAAP
67.52
- -
- -
- -
3.6
- -
48.15
35.6
22.27
23.2
22.16
22.36
23.91
Effective Tax Rate (%)
0.89
-7.33
-5.66
-12.01
8.98
12.1
0.54
5.94
5.77
3.03
6.08
8.34
7.18
Profit Margin (%)
464
416
472
471
537
572
571
665
542
356
334
282
324
Working Capital
3,722
3,534
3,477
1,737
1,745
1,582
1,515
1,442
1,271
1,280
1,292
1,180
1,492
LT Debt
48
-222
-219
1,246
1,524
1,617
1,561
1,671
1,695
1,610
1,693
1,689
1,518
Total Equity
- -
- -
- -
- -
7.55
- -
1.56
4.23
4.93
5.6
6.99
8.73
9.81
Return on Invested Capital (%)
- -
- -
- -
- -
74.56
- -
4.06
14.69
16.29
13.43
28.09
38.22
27.75
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-64.64%
-1.75%
-10.12%
Free Cash Flow
304.44%
4.97%
3.64%
Net Income, GAAP
103.47%
20.67%
-8.38%
Sales/Revenue/Turnover
4.01%
5.21%
6.55%
Total Cash Common Dividend
- -
17.97%
7.69%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2,142
2024
- -
- -
- -
- -
2,289
2025
- -
- -
- -
- -
2,439

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.26
2024
- -
- -
- -
- -
0.37
2025
- -
- -
- -
- -
0.35

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.22
2024
- -
- -
- -
- -
0.25
2025
- -
- -
- -
- -
0.28
Similar Companies
Fielmann AG (FLMNF)
Poly Medicure Limited (POLYMED.NS)
Zhejiang Gongdong Medical Technology Co.,Ltd. (605369.SS)
American Medical Technologies Inc. (ADLI)
The Cooper Companies, Inc. (0I3I.L)
Encision Inc. (ECIA)
Business
ConvaTec Group Plc (CTEC; CNVVY) develops, manufactures and markets medical products and technologies focused on therapies for chronic disease management; it offers advanced wound care solutions including dressings for acute and chronic wounds from conditions such as diabetes, trauma and burns; ostomy care products encompassing devices, accessories and services for stoma patients resulting from colorectal or bladder cancer, inflammatory bowel disease and trauma; continence care items for urinary issues linked to spinal cord injuries, neurological diseases and prostate enlargement; and infusion care comprising disposable sets for insulin pumps in diabetes treatment or continuous infusions for Parkinson's disease. The FTSE 100 company, founded in 1978 and headquartered at 7th Floor, 20 Eastbourne Terrace, London W2 6LG, United Kingdom, employs approximately 10,000 people and operates in more than 100 countries with net sales distributed across Europe/Middle East/Africa (29%), Americas (57%) and Asia/Pacific (15%). Recent developments include the July 2025 receipt of US FDA 510(k) clearance, CE mark, UKCA mark and Australian TGA approval for AQUACEL ConvaFiber, a next-generation wound care product; the August 2025 launch of a $300 million share buyback programme running through December 2025 to return surplus capital to shareholders; and the November 2025 secondary offering where institutional investors acquired a 7.8% stake from Novo Holdings for £351 million.

Company News

MCPAPIChat

  • seekingalpha.com

    Convatec Group PLC (CNVVY) ConvaTec Group PLC, 4 Months Period Ending/ Trading Statement Call Transcript

  • reuters.com

    Medical product maker Convatec warns of higher cost from Iran War

  • proactiveinvestors.co.uk

    ConvaTec falls despite backing outlook

  • businesswire.com

    Convatec's Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 2026

  • seekingalpha.com

    Convatec Group PLC (CNVVY) Analyst/Investor Day Transcript

  • proactiveinvestors.co.uk

    Leading bank sees Convatec investor meting as credibility test for growth targets

  • businesswire.com

    Convatec Introduces Co-Branded eakin freeseal® Ostomy Seal in North America, Expanding the ESENTA™ Family of Accessories

  • seekingalpha.com

    Convatec Group PLC (CNVVY) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    ConvaTec Group (OTCMKTS:CNVVY) Trading Up 1.6% – What’s Next?

  • seekingalpha.com

    Artisan International Small-Mid Fund Q3 2025 Performance Review

  • seekingalpha.com

    ConvaTec Group PLC (CNVVY) 10 Months 2025 Sales/ Trading Statement Call Transcript

  • seekingalpha.com

    ConvaTec Group PLC (CNVVF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    ConvaTec Group PLC (CNVVF) Q4 2023 Earnings Call Transcript

  • seekingalpha.com

    ConvaTec Group Plc (CNVVF) CEO Karim Bitar on Q2 2022 Results - Earnings Call Transcript